Skip to main content

Table 2 Distribution of antibodies in pre-RA cases stratified by time to RA (dichotomized at median of duration between Ab testing and RA diagnosis, i.e. 7 years). Cut-offs are based on the 98th percentile of controls with the exception of anti-CCP2 antibodies where the manufacturer’s cut-off was applied, and RF where a titre of 1:40 was considered positive. RF; rheumatoid factor. CEP1, cFib and cVim; citrullinated peptides from α-enolase, fibrinogen and vimentin respectively. REP1, Fib and Vim are the arginine-containing control peptides. CPP3 and CPP5 are immunodominant peptides from PPAD, and RPP3 and RPP5 are the arginine-containing control peptides. RgpB; arginine gingipain

From: Smoking, Porphyromonas gingivalis and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case–control study

Antibodies

Time to diagnosis

 
 

Time <7 years n = 51

Time ≥ 7 years n = 52

p-value

RF n (%)

15 (29)

9 (18)

0.179

CCP2 n (%)

15 (27)

10 (20)

0.298

CEP1 n (%)

11 (21)

4 (8)

0.056

REP1 n (%)

2 (4)

0 (0)

0.157

cFib n (%)

13 (25)

6 (12)

0.092

Fib n (%)

1 (2)

1 (2)

0.978

cVim n (%)

4 (10)

1 (3)

0.204

Vim n (%)

3 (6)

1 (2)

0.278

CPP3 n (%)

1 (2)

1 (2)

0.989

RPP3 n (%)

3 (6)

2 (4)

0.663

CPP5 n (%)

2 (4)

3 (6)

0.631

RPP5 n (%)

0 (0)

2 (4)

0.149

RgpB n (%)

2 (4)

1 (2)

0.569

RgpB quartiles

  1 (<1280)

25 (48)

26 (51)

0.571

  2 (≥1280)

17 (33)

12 (24)

  3 (≥2560)

8 (15)

12 (24)

  4 (≥5120)

2 (4)

1 (2)

RgpB (u/ml), median (IQR)

1280 (713–1946)

1174 (468–2560)

0.449